Literature DB >> 20614802

Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies.

Susanne Nikolaus1, Christina Antke, Markus Beu, Hans-Wilhelm Müller.   

Abstract

Various factors are discussed in the pathophysiology of anxiety disorders, including dysfunctions of the (DA)ergic, serotonin (5-HT)ergic and GABAergic system. We assessed the contribution of the individual synaptic constituents by subjecting all available in vivo imaging studies on patients with anxiety disorders to a retrospective analysis. On a total of 504 patients with obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder (PD), phobia, or posttraumatic stress-disorder (PTSD) and 593 controls, investigations of VMAT2, DAT, SERT, D1, D2, 5-HTIA, 5-HT2A, GABA(A), and NK1 receptor binding in neostriatum, ventral striatum, thalamus, neocortex, limbic system, cingulate, midbrain/ pons or cerebellum were performed using either PET or SPECT. Separate analyses of the individual disorders showed significant decreases of striatal D2 receptors in OCD (-18%), mesencephalic SERT in OCD (-13%), frontocortical GABAA receptors in PD (-13%) and temporocortical GABAA receptors in GAD (-16%). Pooling of all disorders yielded a significant reduction of mesencephalic SERT (-13%), mesencephalic (-27%) as well as cingulate 5-HT1A receptors (-18%), striatal D2 receptors (-21%) and frontal (-14%), temporal (-14%), occipital (-13%) and cingulate GABAA receptors (-15%). The results show that DA, 5-HT, and GABA play a major role in all subtypes of anxiety disorders. In particular, the findings imply that the regulation state of DA as modulated by GABA and 5-HT may be crucial for the development of anxiety- and compulsion-related disorders. As GABA and 5-HT inhibit DAergic neurotransmission, the reductions of GABAA, 5-HT1A and SERT can be assumed to result in an enhanced activity of the mesolimbic DAergic system. This notion is also reflected by the decrease of striatal D2 receptor binding, which is indicative of an increased availability of synaptic DA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614802     DOI: 10.1515/revneuro.2010.21.2.119

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  75 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.

Authors:  Thomas Dresler; Anne Guhn; Sara V Tupak; Ann-Christine Ehlis; Martin J Herrmann; Andreas J Fallgatter; Jürgen Deckert; Katharina Domschke
Journal:  J Neural Transm (Vienna)       Date:  2012-06-13       Impact factor: 3.575

Review 3.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

4.  Striatal dopamine type 2 receptor availability in anorexia nervosa.

Authors:  Allegra Broft; Mark Slifstein; Joseph Osborne; Paresh Kothari; Simon Morim; Rebecca Shingleton; Lindsay Kenney; Shankar Vallabhajosula; Evelyn Attia; Diana Martinez; B Timothy Walsh
Journal:  Psychiatry Res       Date:  2015-07-26       Impact factor: 3.222

5.  GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment.

Authors:  Ravid Doron; Avital Sever; Assaf Handelsman; Roni Toledano; Motty Franko; Yafit Hirshler; Alon Shamir; Or Burstein; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2018-05-08       Impact factor: 3.444

6.  Dopaminergic control of anxiety in young and aged zebrafish.

Authors:  Victoria Kacprzak; Neil A Patel; Elizabeth Riley; Lili Yu; Jing-Ruey J Yeh; Irina V Zhdanova
Journal:  Pharmacol Biochem Behav       Date:  2017-04-10       Impact factor: 3.533

Review 7.  Neuromodulation for obsessive-compulsive disorder.

Authors:  Kyle A B Lapidus; Emily R Stern; Heather A Berlin; Wayne K Goodman
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 8.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

9.  Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.

Authors:  Ammar Imad Hazim; Surash Ramanathan; Suhanya Parthasarathy; Mustapha Muzaimi; Sharif Mahsufi Mansor
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

10.  Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation.

Authors:  P Trifilieff; B Feng; E Urizar; V Winiger; R D Ward; K M Taylor; D Martinez; H Moore; P D Balsam; E H Simpson; J A Javitch
Journal:  Mol Psychiatry       Date:  2013-05-28       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.